Company Overview and News

Angkor Reports On Initial Exploration Program on Koan Nheak Gold Property

2018-01-08 marketwired
SEXSMITH, AB--(Marketwired - January 08, 2018) - Angkor Gold Corp. (TSX VENTURE: ANK) and (OTC: ANKOF) ("Angkor" or "the Company") CEO Mike Weeks is pleased to announce the results of initial exploration out on its Koan Nheak property located in the Mondulkiri Province, Cambodia. Exploration was carried out by Emerald Resources NL (ASX: EMR) ("Emerald") through its Cambodian subsidiary, Renaissance Minerals (Cambodia) Ltd ("Renaissance"), under a Definitive Earn-In Agreement with Angkor announced July 12, 2017.
Upvote Downvote

Angkor Announces Termination of Earn-In Agreement With Blue River Resources Ltd.

2017-11-13 marketwired
SEXSMITH, AB--(Marketwired - November 13, 2017) - Angkor Gold Corp. (TSX VENTURE: ANK) and (OTC PINK: ANKOF) ("Angkor" or "the Company") CEO Mike Weeks announced today the termination of the Company's earn-in exploration agreement with Blue River Resources Ltd. (TSX VENTURE: BXR) on Angkor's wholly-owned Banlung License, which includes the Okalla East and Okalla West Prospects.
Upvote Downvote

Emmerson Resources aims for gold production this quarter

Emmerson Resources (ASX:EMR) will continue its focus in the current December quarter on its New South Wales copper-gold projects and its Tennant Creek gold-copper project in Northern Territory.
Upvote Downvote

Emmerson Resources' Rob Bills talks investor interaction and gold production plans in Proactive Q&A Sessions™

Emmerson Resources Ltd (ASX:EMR) attended and presented at the 2017 Beavor Creek Precious Metals Summit this week.
Upvote Downvote

Angkor Gold and Renaissance Minerals Receive Government Approval For The Koan Nheak Joint Exploration Agreement

2017-09-20 marketwired
SEXSMITH, AB--(Marketwired - September 20, 2017) - Angkor Gold Corp. (TSX VENTURE: ANK) (OTC PINK: ANKOF) ("Angkor" or "the Company") CEO Mike Weeks is pleased to announce that Angkor has received the approval of the Cambodian Ministry of Mines and Energy to proceed with its joint project with Renaissance Minerals (Cambodia) Ltd ("Renaissance") on Angkor's wholly-owned Koan Nheak property. The approval of the Cambodian Ministry of Mines and Energy ("MME") clears the way for Angkor and Renaissance to proceed with their joint exploration plans of Koan Nheak under their Definitive Earn-In Agreement (the Agreement) announced July 12, 2017.
Upvote Downvote

Angkor Signs Definitive Earn-In Agreement with Renaissance Minerals on Koan Nheak Property

2017-07-12 marketwired
SEXSMITH, AB--(Marketwired - July 12, 2017) - Angkor Gold Corp. (TSX VENTURE: ANK) (OTC PINK: ANKOF) ("Angkor" or "the Company") CEO Mike Weeks is pleased to announce that Angkor has entered into a Definitive Earn-In Agreement (the Agreement) with Australian-based gold company, Emerald Resources NL (ASX: EMR) ("Emerald"), on Angkor's wholly-owned Koan Nheak property in northeastern Cambodia.
Upvote Downvote

Emerald Resources NL delivers compelling Okvau Gold feasibility study

Emerald Resources NL (ASX:EMR) has successfully completed the definite feasibility study (DFS) on its Okvau Gold Project in eastern Cambodia.
Upvote Downvote

Emerald Resources NL to provide gold update from Cambodia

Emerald Resources NL (ASX:EMR) has been granted a trading halt by the ASX, pending an update on the Definitive Feasibility Study at the wholly-owned Okvau Gold Project in Cambodia.
Upvote Downvote

Emerald Resources NL to complete Renaissance Minerals takeover

Emerald Resources NL (ASX:EMR) has become the registered holder of 96% of the fully paid ordinary shares of Renaissance Minerals Ltd (ASX:RNS) as part of a takeover offer. Emerald will now acquire the remaining Renaissance shares it did not acquire under the takeover offer in accordance with the compulsory acquisition provisions in the Corporations Act. Renaissance shareholders received 1.55 new Emerald shares for every 1 Renaissance share as part of the off-market takeover offer.
Upvote Downvote

Emerald, Renaissance to merge

Two local gold hopefuls with interests in a Cambodian project have announced a merger, with Emerald Resources to buy Renaissance Minerals in a deal valued at about $40 million.
Upvote Downvote

Renaissance Minerals Ltd granted halt pending corporate transaction

Renaissance Minerals Ltd (ASX:RNS) is targeting large gold systems in an emerging intrusive related gold province in Cambodia.
Upvote Downvote

Emerald Resources NL granted an ASX trading halt

Emerald Resources NL (ASX:EMR) has been granted a trading halt by the ASX today, pending details in relation to a potential material transaction by the company. The halt will remain in place until the opening of trade on Wednesday 20th July 2016, or earlier if an announcement is made to the market. In May 2016, Emerald Resources commenced a gold exploration drilling program at the Okvau deposit which is located in Cambodia.
Upvote Downvote

Emerald Resources NL shares surge after Cambodia gold project gets green light

Cashed up Emerald Resources NL (ASX:EMR) shares surged after relisting on the ASX, following the satisfaction of all conditions precedent to the JV agreement with Renaissance Minerals Ltd (ASX:RNS) over the Okvau gold deposit in Cambodia. Emerald and Renaissance will move forward with an exploration program to upgrade the 1.13 million ounces of gold at 2.2. g/t indicated and inferred resource estimate at the Okvau Deposit.
Upvote Downvote

ASX Notice

Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...